help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stefferl, A.
Right arrow Articles by Reul, J. M. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefferl, A.
Right arrow Articles by Reul, J. M. H. M.
Endocrinology Vol. 140, No. 11 4932-4938
Copyright © 1999 by The Endocrine Society


ARTICLES

Susceptibility and Resistance to Experimental Allergic Encephalomyelitis: Relationship with Hypothalamic-Pituitary-Adrenocortical Axis Responsiveness in the Rat2

Andreas Stefferl1, Christopher Linington, Florian Holsboer and Johannes M. H. M. Reul

Max Planck Institute of Psychiatry, Section of Neuroimmunoendocrinology, D-80804 Munich, Germany; and the Department of Neuroimmunology, Max Planck Institute of Neurobiology (C.L.), D-82152 Martinsried, Germany

Address all correspondence and requests for reprints to: Dr. J. M. H. M. Reul, Max Planck Institute of Psychiatry, Section of Neuroimmunoendocrinology, Kraepelinstrasse 2–10, D-80804 Munich, Germany. E-mail: reul{at}mpipsykl.mpg.de


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Susceptibility to experimental allergic encephalomyelitis (EAE) may be influenced by variations in the production of endogenous glucocorticoids. We investigated whether this concept is consistent across different genotypes and paradigms of EAE. In the major histocompatibility complex-disparate rat strains, Lewis (LEW), Brown Norway (BN), and Dark Agouti (DA), inflammatory and inflammatory-demyelinating variants of EAE were induced by immunization with myelin basic protein and myelin oligodendrocyte glycoprotein, respectively. We analyzed hormone production in EAE and after exposure to novel environment. DA and BN rats showed a robust hypothalamic-pituitary-adrenocortical (HPA) axis response to novelty stress and produced significantly higher ACTH and corticosterone plasma levels compared with LEW rats. However, HPA axis responsiveness was not associated with a generalized resistance to EAE, as both DA and LEW rats were susceptible to myelin basic protein-induced EAE. Moreover, both robust HPA responder strains, DA and the EAE-resistant BN rat, were highly susceptible to myelin oligodendrocyte glycoprotein-induced EAE. In animals of all strains, clinical disease was associated with significantly elevated plasma levels of corticosterone, and no differences in brain glucocorticoid-binding receptors were detected. Therefore, HPA axis characteristics are not a predictor of disease susceptibility in EAE.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
SUSCEPTIBILITY to T cell-mediated autoimmune diseases is influenced by genetic and environmental factors. The genetic influence can be attributed to the major histocompatibility complex (MHC) haplotype (1, 2, 3) as well as poorly defined background genes (4, 5, 6) that may be directly related to immune functions or, alternatively, influence other aspects of disease induction. One immunoregulatory system that has been linked to autoimmunity is the hypothalamic-pituitary-adrenocortical (HPA) axis (7, 8, 9). Its products, the endogenous glucocorticoids (GCs), are among the most potent antiinflammatory agents known and play a vital role in regulating inflammatory processes (7, 8, 10, 11).

Several observations indicate that HPA axis function may be one factor influencing susceptibility to autoimmune diseases. Originally, this concept was derived from studies on adjuvant-induced arthritis in the Lewis (LEW) and Fischer (F344) rat strains (12, 13, 14). Intriguingly, these animals show reciprocal characteristics in terms of their HPA axis response and susceptibility to arthritis; whereas F344 rats mount a robust HPA axis response and are resistant to arthritis, LEW rats exhibit a blunted response and are highly susceptible. The possible importance of the HPA axis in determining disease susceptibility in this strain combination is underlined by the fact that LEW and F344 rats share a similar MHC locus (RT1l and RT1lv1, respectively) (15), which is crucially involved in the induction of pathogenic autoimmune responses. The concept that low HPA axis responsiveness is a general predictor of an increased susceptibility to autoimmune diseases was further supported by studies on experimental autoimmune encephalomyelitis (EAE). The EAE-resistant rat strains Brown Norway (BN) or PVG are both characterized by a robust HPA axis response (9, 16), whereas LEW rats are highly susceptible (9, 11, 16). In this paradigm, all three strains have different MHC haplotypes (15), indicating that the HPA axis may be the deciding influence determining disease susceptibility. Clearly, if a blunted HPA axis response was a predisposing factor for autoimmune disease, this would have a major clinical impact in terms of both prediction and the development of novel therapeutic strategies. However, a prerequisite for the clinical application of this hypothesis would be its consistence across a spectrum of genotypes that mimics the genetic diversity of man. We therefore investigated the association between HPA axis responsiveness and disease susceptibility using two different EAE paradigms in three MHC-disparate rat strains: LEW (RT1l), BN (RT1n), and Dark Agouti (DA; RT1av1). In the rat, the classical EAE paradigm, immunization with myelin basic protein (MBP), leads to inflammatory disease mediated by invading T cells and macrophages (17). In contrast, the novel EAE paradigm induced by immunization with myelin oligodendrocyte glycoprotein (MOG) is mediated by the synergy of inflammatory cells with demyelinating anti-MOG antibodies (17). MOG-induced EAE closely reproduces the demyelinating pathology of the multiple sclerosis (MS) lesion, and therefore serves as a more adequate animal model of MS (17, 18, 19).

We report that HPA axis responsiveness to a mild psychological stressor, exposure to novelty, does not predict susceptibility to EAE. Moreover, both the HPA axis response to EAE and central nervous system (CNS) GC-binding receptors appear normal in all strains analyzed.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Rats and antigens
Female LEW, BN, and DA rats were purchased from Charles River Laboratories, Inc. (Sulzfeld, Germany). The animals were used at 8–12 weeks of age and kept under standardized environmental conditions (lights on from 0600–2000 h; temperature, 23 C; humidity, 40–60%) with free access to food and water in groups of five to seven per Macrolon-type cage [size, ~56 x 34 x 20 cm (length x width x h)]. All experimental procedures were approved by the Bavarian government and performed in compliance with international animal welfare standards. Complete Freund’s adjuvant (CFA) and heat-killed Mycobacterium tuberculosis (H37Ra) were purchased from Life Technologies, Inc. (Rockville, MD). Purified protein derivative was purchased from the State Serum Institute (Copenhagen, Denmark). Whole MBP was purified from guinea pig brain (20). Recombinant protein corresponding to the N-terminal sequence of rat MOG (amino acids 1–125) was expressed in Escherichia coli and purified to homogeneity (21). The purified protein in 6 M urea was then dialyzed against 20 mM sodium acetate buffer (pH 3.0) to obtain a soluble preparation that was stored frozen at -20 C.

Induction of EAE
Guinea pig MBP (50 µg/rat) or recombinant rat MOG (50 µg/rat) corresponding to the extracellular IgG-like domain (amino acids 1–125) of the native protein were emulsified in CFA containing heat-killed Mycobacterium tuberculosum (H 37Ra; 225 µg/rat) and injected sc at the base of the tail in a total volume of 100 µl. Control animals were injected with an emulsion of PBS in CFA. Clinical disease was scored on the following scale: 0.5, partial loss of tail tone; 1.0, complete tail atony; 2.0, hind limb weakness; 3.0, hind limb paralysis; and 4, moribund. Experiments were terminated when more than 30% of animals showed a clinical score greater than 3 for more than 24 h or when disease progression was very rapid and severe. The incidence of adjuvant-induced arthritis was low (<10%) using the base of the tail as an immunization site, but animals exhibiting signs of arthritis were excluded from further analysis.

Measurement of hormone levels
For determining plasma levels of ACTH and corticosterone (CORT), great care was taken to keep rats undisturbed the night before the experiment. The animals were anesthetized in a glass jar containing saturated halothane (Hoechst, Frankfurt am Main, Germany) immediately after removal from their home cage between 0700–0800 h; Trunk blood was collected after decapitation in ice-chilled, EDTA-coated tubes containing 140 µg aprotinin (Trasylol, Bayer Corp., Leverkusen, Germany). The whole procedure was performed in less than 30 sec. To induce novelty stress, animals were taken from their home cage and placed individually in new cages for 30 min before collecting trunk blood. This time point represents peak plasma levels of corticosterone, which for this study is the most important HPA hormone, and the descending slope of plasma ACTH levels. It has been shown previously that at 30 min during novelty stress, corticosterone and ACTH responses show parallel changes (22, 23). Blood samples were centrifuged at 4 C for 10 min, and plasma aliquots were stored at -80 C for analysis by RIA (ICN Biomedicals, Inc., Costa Mesa, CA). The inter- and intraassay coefficients of variance for ACTH were 7% and 5%, respectively, with a detection limit of approximately 2 pg/ml. For CORT, the inter- and intraassay coefficients of variance were 7% and 4%, respectively, with a detection limit of 0.15 µg/100 ml.

Surgery and [3H]steroid binding assay
For corticosteroid binding measurement, naive rats were bilaterally adrenalectomized under halothane anesthesia to deplete their body of endogenous corticosteroids. After surgery, drinking water was supplemented with 0.9% NaCl. Twenty-four hours after adrenalectomy the animals were anesthetized with halothane and decapitated. Trunk blood was collected, plasma samples were prepared as described above, and the absence of CORT was verified by RIA. Immediately after decapitation, the hippocampus, hypothalamus, frontal cortex, amygdala, and the anterior pituitary were dissected, snap-frozen in liquid nitrogen, and stored at -80 C. The samples were homogenized (100 mg wet weight/ml) in 5 mM Tris-HCl (pH 7.4) containing 5% glycerol, 10 mM sodium molybdate, 1 mM EDTA, and 2 mM ß-mercaptoethanol using an ice-cooled glass homogenizer with a Teflon pestle (10 strokes at 900 rpm). The homogenate was centrifuged at 100,000 x g at 2 C for 60 min, and the supernatant (cytosol) was collected. All of the following steps were performed at 2–4 C.

Mineralocorticoid receptors (MR) were measured in aliquots of cytosol incubated in duplicate for 20–24 h with [3H]aldosterone (84 Ci/mmol; NEN Life Science Products DuPont, Dreiech, Germany) in a concentration range of 0.1–10 nM in the presence of a 100-fold excess of the specific glucocorticoid receptor (GR) ligand RU28362 [11ß,17ß-dihydroxy-6-methyl-17{alpha}-(1-propionyl)androsta-1,4,6-triene-3-one] to prevent [3H]aldosterone from binding to GR. Nonspecific binding was assessed by incubating cytosol with [3H]aldosterone in the presence of a 1000-fold excess of unlabeled CORT.

Binding to the cytosolic GR was determined by incubation in duplicate with [3H]dexamethasone (86 Ci/mmol; Amersham Pharmacia Biotech, Braunschweig, Germany) at concentrations ranging from 0.2–10 nM. The binding of dexamethasone to MR was evaluated by adding a 100-fold excess of RU 28362. Nonspecific binding was assessed by adding a 1000-fold excess of unlabeled dexamethasone.

After the incubation period, bound and free [3H]steroid were separated by gel filtration on Sephadex LH-20 (Pharmacia Biotech, Uppsala, Sweden), and bound radioactivity was measured by liquid scintillation counting. The protein content of the aliquots was determined by the method of Lowry, using BSA as a standard.

The binding data were expressed as femtomoles per mg protein, and nonspecific binding was subtracted from total binding to yield specific binding. GR levels were calculated by subtraction of nonspecific binding as well as binding of [3H]dexamethasone to MR. Total binding (Bmax) and binding affinity (Kd) were derived from Scatchard analysis.

Data presentation and statistical analysis
Data are presented as the group mean ± SEM; group sizes are 8–10 in all experiments. Means were compared by one- or two-way ANOVA and Duncan’s post-hoc test as indicated.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The HPA axis response to novelty stress is strain dependent
The characteristics of the HPA axis response to novelty stress were determined in naive DA, BN, and LEW rats (n = 8 in all groups). Basal levels of ACTH (Fig. 1aGo) were similar in BN and DA rats (60.8 ± 12.2 and 50 ± 8 pg/ml, respectively), whereas the LEW rat produced lower baseline levels of ACTH [27.3 ± 7.1 pg/ml; by one-way ANOVA: F(1, 14) = 3.32, P = 0.055, by Duncan’s post-hoc test: P < 0.05]. Thirty minutes of novelty stress induced a pronounced increase in plasma levels of ACTH in all three rat strains [by two-way ANOVA: effect of strain: F(2, 40) = 6.75, P = 0.003; effect of stress: F(1, 40) = 38.01, P <= 0.0005; two-way interaction: F(2, 40) = 3.99, P = 0.026; Fig. 1aGo]. In BN and DA rats plasma ACTH reached comparable levels (346 ± 63.3 and 306.5 ± 86.2 pg/ml, respectively), whereas the rise of ACTH in LEW rats was significantly less [103.4 ± 28.7 pg/ml; by one-way ANOVA: F(2, 42) = 8.67, P = 0.001] than that in DA and BN rats (P < 0.05, by Duncan’s post-hoc test).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 1. Basal and novelty stress induced plasma levels of ACTH (a) and CORT (a) in LEW, DA, and BN rats. Animals (n = 8–10) of all three strains were either killed under stress-free early morning conditions to obtain basal plasma levels of ACTH (a) and CORT (b) or were subjected to 30 min of novelty stress to assess stress-induced ACTH and CORT levels as described in Materials and Methods. *, P < 0.05, by Duncan’s post-hoc test comparing all strains.

 
Plasma CORT levels followed a similar stress-response pattern as ACTH (Fig. 1bGo), but strain differences were more pronounced. In undisturbed animals, plasma CORT levels were low, ranging from 0.09 ± 0.08 to 0.3 ± 0.16 µg/dl in DA and BN rats, whereas the levels in LEW rats were significantly higher at 1.7 ± 0.7 µg/dl [by one-way ANOVA: F(2, 21) = 5.18, P = 0.015; by Duncan’s post-hoc test, P < 0.05]. Again, stress induced significant elevations of CORT in all strains [by two-way ANOVA: effect of strain: F (2, 42) = 8.67, P = 0.001; effect of stress: F(1, 42) = 82.68, P <= 0.0005; two-way interaction: F(2, 42) = 11.98, P <= 0.0005]. DA and BN rats responded with a similar elevation of circulating hormone levels in response to novelty stress (28.1 ± 4.8 and 21.0 ± 2.7 µg/dl, respectively). In contrast, plasma CORT concentrations in LEW rats reached less than half the levels of the other rat strains [6.7 ± 2 µg/dl; by one-way ANOVA: F(2, 21) = 10.39, P = 0.0007; by Duncan’s post-hoc test, P < 0.05]. These data reproduce earlier work on the depressed function of the HPA axis in the LEW rat (12, 14), and demonstrate that the DA rat, like the BN rat (16, 24), is a high responder strain.

Brain GC receptor levels in DA, LEW, and BN rats are similar
The hippocampus contains high amounts of glucocorticoid-binding receptors and is thought to play an important role in the regulation of the HPA axis by providing tonic inhibitory input to the hypothalamus (25). All three strains revealed comparable levels of hippocampal GR at 120–130 fmol/mg (Table 1Go) with similar affinities of approximately 1 nM (Kd derived from Scatchard analysis). Hippocampal MR densities were also similar (62–72 fmol/mg; Table 1Go) in the three rat strains, and receptor affinity derived from Scatchard analysis was within the expected range of 0.2–0.4 nM.


View this table:
[in this window]
[in a new window]
 
Table 1. Brain glucocorticoid and mineralocorticoid receptors in LEW, DA, and BN rats

 
Analysis of GR and MR binding in the hypothalamus, frontal cortex, and amygdala (Table 1Go) confirmed the finding that receptor levels are similar in BN, DA, and LEW rats, with interstrain variations not exceeding 15%. Levels of GR were similar to those in the hippocampus, ranging from 104–136 fmol/mg, whereas MR levels were lower than those in the hippocampus, ranging from 10–20 fmol/mg in these brain regions.

Finally, levels of GR and MR were determined in the anterior pituitary (Table 1Go), one of the main components of the HPA axis. MR levels were intermediate compared with those in the other brain regions, reaching an average of 26 fmol/mg in BN and DA rats. GR levels in the anterior pituitary were lower compared with those in the CNS regions, reaching approximately 85 fmol/mg in BN and DA rats. In LEW rats, both MR and GR were approximately 30% lower than in the other strains.

HPA axis responsiveness is not a predictor of susceptibility to EAE
Using the classical MBP-induced paradigm of EAE, we confirmed previous studies (11, 26, 27, 28) that reported LEW and DA rats as susceptible and BN rats as highly resistant (Fig. 2aGo). LEW rats developed clinical signs of disease as early as 9 days postimmunization [pi; mean clinical score (mcs), 0.8 ± 0.3], which reached a severity of mcs = 3.4 ± 0.1 on day 13 pi. Disease in DA rats was slightly delayed, with the first signs of paralysis on days 11–12 pi and a mean clinical score of 0.8 ± 0.4 reached on day 13 pi In contrast, none of the BN rats developed any signs of clinical disease. Interestingly, this pattern of resistance/susceptibility does not correlate with the HPA axis characteristics of these strains, as the HPA axis responses to novelty stress in the susceptible DA rat were indistinguishable from those in the resistant BN strain.



View larger version (27K):
[in this window]
[in a new window]
 
Figure 2. Clinical disease in LEW, DA, and BN rats after immunization with MBP (a) or MOG (b). Animals (n = 8–10) were immunized with 50 µg/rat MBP/CFA or MOG/CFA to induce EAE (except for LEW rats, which received 100 µg MOG/CFA) and were monitored daily for clinical signs of disease. At different time points, animals were killed under stress-free conditions to measure plasma hormone levels (see Fig. 3Go). For further experimental details, see Materials and Methods and Results.

 
To investigate whether the HPA axis in any of the strains was compromised in its response to an immunological stimulus compared with the psychological stimulus novelty stress, we measured plasma corticosterone levels 13 days after immunization with MBP (Fig. 3aGo). LEW rats suffering from MBP-induced EAE showed a significant elevation of plasma CORT [9.4 ± 2.4 µg/dl; compared with CFA controls, 3.4 ± 0.8 µg/dl; by one-way ANOVA: F(1, 17) = 5.22, P = 0.036]. This was also the case in DA rats suffering from MBP-induced EAE levels [11.1 ± 2.6 µg/dl; compared with CFA controls, 1.5 ± 0.4 µg/dl; by one-way ANOVA: F(1, 29) = 15.87, P = 0.0004]. In contrast, BN rats failed to exhibit elevated plasma levels of CORT (0.3 ± 0.2 µg/dl vs. 1.8 ± 0.6 µg/dl in controls). Plasma CORT levels in control animals immunized with CFA did not show any strain differences [by one-way ANOVA: F(2, 31) = 1.41, P = 0.26], whereas strain differences existed after immunization with MBP [by one-way ANOVA: F(2, 33) = 7.48, P = 0.0021]. These data indicate that clinical disease in MBP-induced EAE is associated with HPA axis activation in susceptible strains. As no disease activity is induced by immunization with MBP in the BN rat, no conclusion regarding HPA axis activation can be drawn in this strain.



View larger version (33K):
[in this window]
[in a new window]
 
Figure 3. Plasma levels of CORT after EAE induction with MBP (a) or MOG (b; n = 8–10). To investigate the HPA axis response to EAE, animals were killed under stress-free conditions after they had developed clinical disease (compare with Fig. 2Go); control animals immunized with buffer/CFA were killed at corresponding time points, and plasma hormone levels were determined as described in Materials and Methods. a, Plasma hormone levels 13 days after immunization with MBP. b, After immunization with MOG, DA and BN rats had to be killed for hormone measurement 11 and 13 days after immunization due to the severity of symptoms, whereas LEW rats were analyzed 17 days pi. *, P < 0.05, strain differences by Duncan’s post-hoc test; {dagger}, P < 0.05, effect of EAE within one strain comparing CFA vs. EAE (by one-way ANOVA).

 
Despite its use in numerous studies, MBP-induced EAE may not be the most appropriate model of MS, as it fails to induce primary demyelination, a hallmark of MS (17). Furthermore, MBP-EAE is strongly influenced by genetic differences, e.g. MHC-related effects, that may obscure HPA axis influences on strain susceptibility (1, 2, 3). This could explain why the DA rat is susceptible to MBP-induced EAE despite its robust HPA axis response. We therefore also studied a novel EAE paradigm induced by MOG, an encephalitogen that mediates EAE across a wide variety of genotypes (29) and which reproduces the immunopathology of MS (17, 18, 19) Surprisingly, patterns of resistance/susceptibility in the three rat strains differed from those in MBP-induced disease (Fig. 2Go, a and b).

After immunization with MOG (n = 8–10 for all strains), the alleged standard high susceptibility LEW strain did not develop any clinical disease until day 17 pi after immunization with 50 µg MOG/CFA. After immunization with 100 µg MOG/CFA, LEW rats developed a late onset, milder, and less rapidly progressive disease than DA and BN rats, with the onset of clinical symptoms from day 14 pi (Fig. 2bGo). Animals were killed for hormone measurement on day 17 pi (mcs, 2.6 ± 0.2). In contrast, the DA rat developed a highly aggressive disease that progressed rapidly, such that all animals had to be killed on day 11 pi (mcs, 3.4 ± 0.6). Also, BN rats developed severe clinical disease as early as day 9 pi, and on day 13 pi had a mcs of 3.7 ± 0.2 (Fig. 2bGo), which is in striking contrast to their complete resistance to MBP-induced EAE. This enabled us to look for any correlation between HPA axis activity and disease in all three strains in a single disease paradigm.

As with MBP-induced disease, clinical disease was associated with HPA axis activation (Fig. 3bGo). In LEW rats CORT levels remained unchanged until clinical disease developed [1.6 ± 0.6 vs. 3.4 ± 0.8 µg/dl on day 13 pi; by one-way ANOVA: F(1, 17) = 2.6, P = 0.12; 15.9 ± 2.1 vs. 7.4 ± 1.1 µg/dl 17 days pi; by one-way ANOVA: F (1, 15) = 9.7, P = 0.007; Fig. 3bGo]. Both DA [30.4 ± 8 vs. 1.5 ± 0.4 µg/dl on day 11 pi; by one-way ANOVA: F(1, 25) = 28.17, P <= 0.0005] and BN [11.1 ± 1.9 vs. 3.4 ± 0.8 µg/dl on day 13 pi; by one-way ANOVA: F(1, 18) = 23.2, P = 0.0001] rats exhibited marked elevations of plasma CORT on days 11 and 13 pi. Basal levels of CORT were not significantly different between CFA-immunized animals of all strains at the early time points (compare Fig. 3aGo). However, basal CORT was elevated in LEW rats on day 17 pi (3.4 ± 0.8 µg/dl on day 13 pi vs. 7.4 ± 1.1 µg/dl on day 17 pi; by one-way ANOVA: F(3, 37) = 8.027, P = 0.0003], possibly indicating a nonspecific CFA effect at this late time point. EAE-induced CORT levels were different between strains [by one-way ANOVA: F(2, 29) = 5.94, P = 0.0069].


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In this study, we investigated the relationship between HPA axis characteristics and susceptibility to EAE in three MHC disparate inbred rat strains, LEW, DA, and BN, to mimic some of the genetic diversity of a natural population. Furthermore, different paradigms of EAE were employed to reproduce the diversity of immune effector mechanisms and target autoantigens involved in MS (18). We demonstrate that HPA axis characteristics have no predictive value with regard to disease susceptibility for any given strain. Our results show that although the DA rat mounts a robust HPA axis response very similar to the previously studied BN rat, it is highly susceptible to EAE regardless of the paradigm studied. Neither the high HPA axis response of BN rats nor the blunted response of LEW rats was associated with a consistent pattern of resistance/susceptibility in the different disease paradigms. Therefore, it is unlikely that HPA axis characteristics measured by stimulated hormone levels have a general predictive value with regard to disease susceptibility in the human situation.

GCs interact with the immune system at multiple levels and are known to exert both immune suppressive and immune stimulatory effects (30). They influence T cell survival and proliferation, suppress inflammatory cytokines, and have many systemic effects that influence the homeostasis of an organism and hence the environment in which immune responses take place (10, 31). Conversely, immune responses and in particular inflammation stimulate GC production by the HPA axis (32, 33), providing a regulatory feedback loop. This feedback regulation is of vital importance, as abrogation of the endogenous GC response renders animals vulnerable to overshooting inflammatory and immune responses (32). In EAE, CNS inflammation strongly activates the HPA axis, and the resulting elevation of GC levels is necessary for recovery from disease (11). Surgical or pharmacological interruption of this response results in lethal EAE in susceptible strains (11) and can render some resistant strains susceptible to disease induction (9). Conversely, treatment with exogenous GCs can block disease in a dose-dependent fashion (9, 27). In contrast, disruption of endogenous GC homeostasis by GC treatment followed by untapered withdrawal can lead to relapse-induction (27). Clearly, endogenous GCs are of central importance in controlling disease processes in EAE, but it was uncertain whether genetic variations in HPA axis function at the level of either hormone production or the expression of central GC receptors provides a major susceptibility factor for EAE.

In response to the mild psychological stressor novel environment, two different HPA axis response patterns could be discerned in the three strains studied. BN and DA rats mounted a robust HPA axis response as indicated by high circulating levels of ACTH and CORT, whereas the response in LEW rats was blunted. These data confirm published reports on the HPA axis characteristics in LEW and BN rats (9, 12, 14, 16, 24), whereas the HPA axis response of the DA rat had not been investigated previously.

CNS glucocorticoid-binding receptors are of foremost importance in the regulation of the HPA axis (34, 35). Hence, dysregulation/dysfunction in central receptor expression may have far-reaching consequences with respect to immune regulation (10). However, measurement of MR and GR in the hippocampus, hypothalamus, frontal cortex, and amygdala revealed no major differences in receptor densities among LEW, BN, and DA rats, with strain differences not exceeding 15% in any region. Only in the anterior pituitary were marked differences in receptor densities observed among strains, as in the LEW rat levels of both MR and GR were 30% lower than those in the DA or BN rat. The functional significance of this finding with respect to HPA axis function remains to be investigated. Unfortunately, our receptor measurements in female rats cannot be compared directly to the results of previous studies that were generally performed in male rats of other strains. It is well known that both strain and gender can have an influence on brain GC receptor expression (36, 37, 38). Furthermore, major differences in the experimental protocol regarding both the animals (e.g. adrenalectomy 15 days before receptor measurement) (39) and the binding assay itself (e.g. method of separation of bound and unbound steroid) (39) prohibit direct comparison. Nevertheless, previous work using a similar experimental protocol also failed to reveal differences in brain GR and MR binding between male animals of high (F344) and low (LEW) HPA axis responder strains (40). The same researchers report reduced stress-induced nuclear trans-location of GR in LEW compared with F344 rats (37); however, this does not seem to indicate impaired receptor regulation, as it corresponds with significantly lower stress-induced CORT levels in the LEW rat. In summary, there seems to be no indication for a profound genetic effect on the expression of central glucocorticoid receptors in the three rat strains investigated in this study.

After characterization of the HPA axis in the three rat strains, we compared different EAE paradigms, immunization with MBP vs. immunization with MOG, to mimic some of the heterogeneity in immune effector mechanisms involved in MS. In the rat, MBP-induced EAE is a purely inflammatory disease initiated by T cells that mediate a local inflammatory response within the CNS. The neurological deficit is then mediated by products of activated macrophages recruited into the lesion (17). T cells and macrophages are both known to be sensitive to glucocorticoid suppression (10, 41), and pharmacological doses of glucocorticoids can abrogate EAE after immunization with MBP (27). The clinical profiles obtained after immunization with MBP reproduced earlier studies in all three strains (11, 26, 27, 28). However, we did not find a consistent association of high HPA axis responses with resistance to disease, in that BN rats were resistant and DA rats were susceptible to MBP-induced disease despite both having a robust HPA axis response. In contrast, in LEW rats, high disease susceptibility is associated with depressed HPA axis function (42).

Strikingly, this pattern of disease susceptibility (LEW>DA>BN) was completely reversed in MOG-induced EAE. In particular, BN rats are resistant to MBP-induced EAE, but they developed a fulminate, lethal form of EAE after immunization with MOG despite their robust HPA response. In contrast, the LEW rat proved to be much less susceptible to MOG-induced EAE than the other strains and developed a late-onset, milder form of disease. Only the DA rat was susceptible to EAE induced with either MOG or MBP; however, again in this rat strain the general susceptibility to EAE is in stark contrast to its robust HPA axis response. There is, therefore, no clear-cut association of HPA axis characteristics as determined by a psychological stressor and susceptibility to EAE in either of the paradigms investigated in this study. However, it is conceivable that there exist major differences in HPA axis activation by novelty stress and CNS inflammation during EAE. To exclude the possibility that any of the strains fails to respond to the inflammatory stimulus, we measured plasma CORT after induction of EAE. All animals exhibited HPA axis activation coinciding with clinical symptoms of EAE in both MOG- and MBP-induced EAE, indicating that all three strains can respond to CNS inflammation.

The original observation regarding the association of a robust HPA axis response with resistance to autoimmune disease was made in streptococcal cell wall-induced arthritis. These studies compared juvenile LEW and F344 rats (13, 14), which are histocompatible and share very similar MHC haplotypes (15). This led to the assumption that immune reactions in these strains should be similar, and that differences in the HPA axis could account for the differences in susceptibility, a concept that was rapidly extended to EAE (9, 16). However, it is known that MHC-unrelated background genes also have a major influence on disease susceptibility (4, 9, 43), but it is unclear whether they are related to HPA axis function or modulate other disease-related processes. Interestingly, at least in some strains (PVG.RT1u, AO, and BN), the function of the HPA axis is actually irrelevant for disease resistance, as even its complete ablation by adrenalectomy fails to render these strains susceptible to EAE (9, 42). Furthermore, in both the present and earlier studies (16) resistant animals failed to show any signs of HPA axis activation. This indicates that disease resistance may not be directly influenced by differences in HPA axis responsiveness to stress or by differences in basal early morning levels of CORT that were highest in the susceptible LEW rat. However, indirect influences on the general reactivity of the immune system or the development of the immune response after active immunization cannot be excluded. These findings question the general applicability of data derived from stress experiments to disease models characterized by completely different modes of HPA axis activation.

In summary, our data indicate that although a functional HPA axis is crucial to control the disease process in susceptible strains of rats (9, 11), there exists no general association of HPA axis responsiveness with disease susceptibility. This is true both for different disease paradigms in a single inbred rat strain as well as for a single disease paradigm in different strains. Susceptibility to EAE is a strain-specific trait determined by both the genotype and the identity of the target autoantigen. This is of particular importance as it is becoming increasingly clear that in many human autoimmune diseases including MS, no single target autoantigen may exist. Rather, the pathogenic process may involve a mixture of responses to various endogenous antigens (18). Hence, HPA axis characteristics cannot serve a predictive function regarding disease susceptibility in either the experimental or the clinical context.


    Acknowledgments
 
The authors thank Mr. T. Pohl, Ms. C. Conzelmann, and Ms. S. Bicking for their excellent technical assistance.


    Footnotes
 
1 Present address: Brain Research Institute, University of Vienna, Vienna, Austria. Back

2 This work was supported by the Volkswagen Foundation (Grant I/70 543). Back

Received March 30, 1999.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Gasser DL, Newlin CM, Palm J, Gonatas NK 1973 Genetic control of susceptibility to experimental allergic encephalomyelitis in rats. Science 181:872–873[Abstract/Free Full Text]
  2. Williams RM, Moore MJ 1973 Linkage of susceptibility to experimental allergic encephalomyelitis to the major histocompatibility locus in the rat. J Exp Med 138:775–783[Abstract]
  3. Moore MJ, Singer DE, Williams RM 1980 Linkage of severity of experimental allergic encephalomyelitis to the rat major histocompatibility locus. J Immunol 124:1815–1820[Abstract]
  4. Happ MP, Wettstein P, Dietzschold B, Heber-Katz E 1988 Genetic control of the development of experimental allergic encephalomyelitis in rats. Separation of MHC and non-MHC gene effects. J Immunol 141:1489–1494[Abstract]
  5. Oksenberg JR, Seboun E, Hauser SL 1996 Genetics of demyelinating diseases. Brain Pathol 6:289–302[Medline]
  6. Gasser DL, Goldner-Sauve A, Hickey WF 1990 Genetic control of resistance to clinical EAE accompanied by histological symptoms. Immunogen 31:377–382[CrossRef][Medline]
  7. Besedovsky HO, del Rey A 1996 Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 17:64–102[Abstract/Free Full Text]
  8. Cizza G, Sternberg EM 1994 The role of the hypothalamic-pituitary-adrenal axis in susceptibility to autoimmune/inflammatory disease. Immunomethods 5:73–78[CrossRef][Medline]
  9. Mason D, MacPhee IAM, Antoni FA 1990 The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology 70:1–5[Medline]
  10. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL, Weiss JM 1997 The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Rev 23:79–133[CrossRef][Medline]
  11. MacPhee IA, Antoni FA, Mason DW 1989 Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 169:431–445[Abstract/Free Full Text]
  12. Sternberg EM, Wilder RL, Gold PW, Chrousos GP 1990 A defect in the central component of the immune system– hypothalamic-pituitary-adrenal axis feedback loop is associated with susceptibility to experimental arthritis and other inflammatory diseases. Ann NY Acad Sci 594:289–292[Medline]
  13. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL 1989 Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 86:2374–2378[Abstract/Free Full Text]
  14. Sternberg EM, Young WS3, Bernardini R, Calogero AE, Chrousos GP, Gold PW, Wilder RL 1989 A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 86:4771–4775[Abstract/Free Full Text]
  15. Hedrich HJ 1990 Inbred strains of rats and mutants. In: Hedrich HJ (ed) Genetic Monitoring of Inbred Strains of Rats. Gustav Fischer Verlag, Stuttgart and New York, pp 410–487
  16. Villas PA, Dronsfield MJ, Blankenhorn EP 1991 Experimental allergic encephalomyelitis and corticosterone studies in resistant and susceptible rat strains. Clin Immunol Immunopathol 61:29–40[Medline]
  17. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C 1994 Animal models. Ann Neurol [Suppl] 36:S47–S53
  18. Storch MK, Lassmann H 1997 Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 10:186–192[Medline]
  19. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, Olsson T, Linington C, Lassmann H 1998 Autoimmunity to myelin oligodendrocyte glycoprotein mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681–694[Medline]
  20. Eylar EH, Kniskern PJ, Jackson JJ 1974 Myelin basic proteins. Methods Enzymol 32:323–341[Medline]
  21. Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier MV, Matthieu JM, Baker D 1994 Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 153:4349–4356[Abstract]
  22. Reul JMHM, Stec I, Söder M, Holsboer F 1993 Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133:312–320[Abstract/Free Full Text]
  23. Reul JMHM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F 1994 Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60:509–519[Medline]
  24. Gomez F, Lahmame A, De Kloet ER, Armario A 1996 Hypothalamic-pituitary-adrenal response to chronic stress in five inbred rat strains: differential responses are mainly located at the adrenocortical level. Neuroendocrinology 63:327–337[Medline]
  25. Herman JP, Cullinan WE 1997 Neurocircuitry of stress: central control of the hypothalamic-pituitary-adrenocortical axis. Trends Neurosci 20:78–84[CrossRef][Medline]
  26. Stepaniak JA, Gould KE, Sun D, Swanborg RH 1995 A comparative study of experimental autoimmune encephalomyelitis in Lewis and DA rats. J Immunol 155:2762–2769[Abstract]
  27. Reder AT, Thapar M, Jensen MA 1994 A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease [published erratum appears in Neurology 1995 May;45(5):1034]. Neurology 44:2289–2294[Abstract/Free Full Text]
  28. Levine S, Sowinski R, Steinetz B 1980 Effects of experimental allergic encephalomyelitis on thymus and adrenal: relation to remission and relapse. Proc Soc Exp Biol Med 165:218–224[CrossRef][Medline]
  29. Weissert R, Wallström E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, Linington C, Olsson T 1998 MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 102:1265–1273[Medline]
  30. Wiegers GJ, Reul JMHM 1998 Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci 19:317–321[CrossRef][Medline]
  31. Dallman MF, Akana SF, Strack AM, Hanson ES, Sebastian RJ 1995 The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Ann NY Acad Sci 771:730–742[Medline]
  32. Munck A, Guyre PM, Holbrook NJ 1984 Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5:25–44[Abstract/Free Full Text]
  33. Linthorst ACE, Flachskamm C, Holsboer F, Reul JMHM 1995 Intraperitoneal administration of bacterial endotoxin enhances noradrenergic neurotransmission in the rat preoptic area: relationship with body temperature and hypothalamic-pituitary-adrenocortical axis activity. Eur J Neurosci 7:2418–2430[CrossRef][Medline]
  34. De Kloet ER, Reul JMHM 1987 Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology 12:83–105[CrossRef][Medline]
  35. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M 1998 Brain corticosteroid receptor balance in health and disease. Endocr Rev 19:269–301[Abstract/Free Full Text]
  36. Oitzl MS, van Haarst AD, Sutanto W, De Kloet ER 1995 Corticosterone, brain mineralocorticoid receptors (MRs) and the activity of the hypothalamic-pituitary-adrenal (HPA) axis: the Lewis rat as an example of increased central MR capacity and a hyporesponsive HPA axis. Psychoneuroendocrinology 20:655–675[CrossRef][Medline]
  37. Dhabhar FS, Miller AH, McEwen BS, Spencer RL 1995 Differential activation of adrenal steroid receptors in neural and immune tissues of Sprague Dawley, Fischer 344, and Lewis rats. J Neuroimmunol 56:77–90[Medline]
  38. Endres DB, Milholland RJ, Rosen F 1979 Sex differences in the concentrations of glucocorticoid receptors in rat liver and thymus. J Endocrinol 80:21–26[Abstract/Free Full Text]
  39. Smith CC, Omeljaniuk RJ, Whitfield HJJ, Aksentijevich S, Fellows MQ, Zelazowska E, Gold PW, Sternberg EM 1994 Differential mineralocorticoid (type 1) and glucocorticoid (type 2) receptor expression in Lewis and Fischer rats. Neuroimmunomodulation 1:66–73[Medline]
  40. Dhabhar FS, McEwen BS, Spencer RL 1993 Stress response, adrenal steroid receptor levels and corticosteroid-binding globulin levels–a comparison between Sprague-Dawley, Fischer 344 and Lewis rats. Brain Res 616:89–98[CrossRef][Medline]
  41. Wiegers GJ, Labeur MS, Stec IE, Klinkert WE, Holsboer F, Reul JMHM 1995 Glucocorticoids accelerate anti-T cell receptor-induced T cell growth. J Immunol 155:1893–1902[Abstract]
  42. Peers SH, Duncan GS, Flower RJ, Bolton C 1995 Endogenous corticosteroids modulate lymphoproliferation and susceptibility to experimental allergic encephalomyelitis in the Brown Norway rat. Int Arch Allergy Immunol 106:20–24[Medline]
  43. Lorentzen JC, Olsson T, Klareskog L 1995 Susceptibility to oil-induced arthritis in the DA rat is determined by MHC and non-MHC genes. Transplant Proc 27:1532–1534[Medline]



This article has been cited by other articles:


Home page
J. Immunol.Home page
C. Benou, Y. Wang, J. Imitola, L. VanVlerken, C. Chandras, K. P. Karalis, and S. J. Khoury
Corticotropin-Releasing Hormone Contributes to the Peripheral Inflammatory Response in Experimental Autoimmune Encephalomyelitis
J. Immunol., May 1, 2005; 174(9): 5407 - 5413.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. A. Staykova, J. T. Paridaen, W. B. Cowden, and D. O. Willenborg
Nitric Oxide Contributes to Resistance of the Brown Norway Rat to Experimental Autoimmune Encephalomyelitis
Am. J. Pathol., January 1, 2005; 166(1): 147 - 157.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Kerschensteiner, C. Stadelmann, B. S. Buddeberg, D. Merkler, F. M. Bareyre, D. C. Anthony, C. Linington, W. Bruck, and M. E. Schwab
Targeting Experimental Autoimmune Encephalomyelitis Lesions to a Predetermined Axonal Tract System Allows for Refined Behavioral Testing in an Animal Model of Multiple Sclerosis
Am. J. Pathol., April 1, 2004; 164(4): 1455 - 1469.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
Z A Erkut, E Endert, I Huitinga, and D F Swaab
Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis
Multiple Sclerosis, June 1, 2002; 8(3): 229 - 236.
[Abstract] [PDF]


Home page
J. Immunol.Home page
B. Marchetti, M. C. Morale, J. Brouwer, C. Tirolo, N. Testa, S. Caniglia, N. Barden, S. Amor, P. A. Smith, and C. D. Dijkstra
Exposure to a Dysfunctional Glucocorticoid Receptor from Early Embryonic Life Programs the Resistance to Experimental Autoimmune Encephalomyelitis Via Nitric Oxide-Induced Immunosuppression
J. Immunol., June 1, 2002; 168(11): 5848 - 5859.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Stefferl, M. K. Storch, C. Linington, C. Stadelmann, H. Lassmann, T. Pohl, F. Holsboer, F. J. H. Tilders, and J. M. H. M. Reul
Disease Progression in Chronic Relapsing Experimental Allergic Encephalomyelitis Is Associated with Reduced Inflammation-Driven Production of Corticosterone
Endocrinology, August 1, 2001; 142(8): 3616 - 3624.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. T. Bergh, T. Kümpfel, A. Grasser, R. Rupprecht, F. Holsboer, and C. Trenkwalder
Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo-Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1610 - 1615.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stefferl, A.
Right arrow Articles by Reul, J. M. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefferl, A.
Right arrow Articles by Reul, J. M. H. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals